Zacks Research Brokers Lower Earnings Estimates for JAZZ

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – Stock analysts at Zacks Research cut their Q3 2026 earnings estimates for shares of Jazz Pharmaceuticals in a research note issued to investors on Monday, August 24th. Zacks Research analyst Team now expects that the specialty pharmaceutical company will earn $5.35 per share for the quarter, down from their prior forecast of $5.49. The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $21.66 per share. Zacks Research also issued estimates for Jazz Pharmaceuticals’ Q4 2026 earnings at $5.29 EPS, FY2026 earnings at $20.77 EPS, Q1 2027 earnings at $4.30 EPS, Q2 2027 earnings at $5.44 EPS, Q3 2027 earnings at $5.16 EPS, Q4 2027 earnings at $5.12 EPS, FY2027 earnings at $20.02 EPS, Q1 2028 earnings at $4.92 EPS, Q2 2028 earnings at $6.09 EPS and FY2028 earnings at $22.74 EPS.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.18 by ($0.47). Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.11 billion. During the same quarter last year, the business posted ($8.25) EPS. The business’s quarterly revenue was up 15.5% compared to the same quarter last year.

Other equities research analysts have also issued research reports about the company. JPMorgan Chase & Co. lifted their price target on Jazz Pharmaceuticals from $265.00 to $276.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft increased their price objective on Jazz Pharmaceuticals from $287.00 to $300.00 and gave the company a “buy” rating in a research report on Wednesday. Truist Financial boosted their target price on Jazz Pharmaceuticals from $264.00 to $281.00 and gave the stock a “buy” rating in a research report on Wednesday. Morgan Stanley upped their target price on Jazz Pharmaceuticals from $283.00 to $322.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, Sanford C. Bernstein reiterated a “market perform” rating on shares of Jazz Pharmaceuticals in a research report on Tuesday, June 9th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $279.00.

Jazz Pharmaceuticals Stock Down 4.2%

JAZZ opened at $249.29 on Thursday. The stock has a market cap of $16.18 billion, a PE ratio of 17.19, a P/E/G ratio of 0.23 and a beta of 0.32. The company has a quick ratio of 1.58, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. Jazz Pharmaceuticals has a 52 week low of $123.87 and a 52 week high of $266.38. The business’s fifty day simple moving average is $246.38 and its 200 day simple moving average is $217.52.

Institutional Trading of Jazz Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. California State Teachers Retirement System grew its holdings in shares of Jazz Pharmaceuticals by 24,585.6% in the second quarter. California State Teachers Retirement System now owns 15,714,136 shares of the specialty pharmaceutical company’s stock worth $3,786,635,000 after purchasing an additional 15,650,479 shares during the last quarter. Capital World Investors raised its holdings in Jazz Pharmaceuticals by 4.4% during the 4th quarter. Capital World Investors now owns 2,666,602 shares of the specialty pharmaceutical company’s stock valued at $453,322,000 after buying an additional 111,735 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in Jazz Pharmaceuticals by 11.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock valued at $198,159,000 after buying an additional 191,637 shares during the last quarter. Franklin Resources Inc. boosted its position in Jazz Pharmaceuticals by 164.0% during the 4th quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock valued at $309,215,000 after buying an additional 1,129,995 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in Jazz Pharmaceuticals by 44.5% during the 1st quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock valued at $317,485,000 after buying an additional 517,514 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Transactions at Jazz Pharmaceuticals

In other news, Director Mark Douglas Smith sold 1,157 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $230.55, for a total value of $266,746.35. Following the completion of the sale, the director owned 9,680 shares of the company’s stock, valued at approximately $2,231,724. The trade was a 10.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $231.83, for a total value of $278,196.00. Following the sale, the executive vice president owned 51,549 shares of the company’s stock, valued at $11,950,604.67. This represents a 2.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 14,357 shares of company stock worth $3,505,642. Company insiders own 4.10% of the company’s stock.

Key Headlines Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: The FDA approved two Ziihera (zanidatamab-hrii) regimens for first-line treatment of adults with unresectable, locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma. The approval covers Ziihera with tislelizumab and chemotherapy for all eligible HER2-positive patients, as well as Ziihera with chemotherapy for a narrower subgroup. The expanded indication substantially increases Ziihera’s addressable market and could support blockbuster sales. FDA Ziihera approval
• Positive Sentiment: Analysts raised their price targets following the approval. Needham lifted its target to $310 from $292 and maintained a Buy rating, while Truist raised its target to $281 from $264 and also rated the stock Buy. The revisions indicate increased expectations for Ziihera’s revenue contribution and Jazz’s growth outlook. Analyst price-target increases
• Neutral Sentiment: Brokerage coverage remains broadly favorable, with Jazz receiving an average Buy recommendation. However, the rating may already reflect some of the optimism surrounding Ziihera’s approval. Average Buy recommendation
• Negative Sentiment: Jazz announced a private offering of $1.0 billion of exchangeable senior notes due 2032, with an option for purchasers to acquire an additional $150 million. Although the proceeds are intended to support concurrent ordinary-share repurchases, the financing increases leverage and creates potential future share dilution, weighing on the stock’s near-term reaction. Exchangeable-notes offering

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.